Noema Pharma
Clinical-stage biopharmaceutical company developing novel therapies for neurological and psychiatric disorders with high unmet need, including tinnitus, autism spectrum disorder, and treatment-resistant depression.
Website
https://www.noemapharma.comLocation
Basel, Switzerland
Founded
2018
Investors
1
Categories
biotech, neuroscience, psychiatric-disorders, neurological-disorders
Notes
Noema Pharma is a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological and psychiatric conditions with significant unmet medical need. The company's pipeline includes therapies for tinnitus, autism spectrum disorder (ASD), and treatment-resistant depression.
Based in Basel, Switzerland, Noema leverages deep expertise in neuroscience and psychiatry to advance differentiated therapies targeting the nervous system.
Team
- Henri Isaacs - Chief Executive Officer
- LinkedIn: linkedin.com/in/henri-isaacs
- Georg Golor, M.D. - Chief Medical Officer
- Antoine Bhawji - Chief Financial Officer
Additional Research Findings
- Founded in 2018 in Basel, Switzerland
- Lead program NOE-105 for chronic tinnitus - Phase 2 studies
- Pipeline includes programs for autism spectrum disorder and treatment-resistant depression
- Backed by Polaris Partners, Sofinnova Partners, and other leading healthcare investors
- Raised over CHF 115 million in Series B financing (2021)
- Focus on conditions with limited treatment options
- European-based with global development strategy
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |